Professor John Chester

2022

• Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25, pp. 43-56. (10.1016/j.omto.2022.03.007)

2021

• Davies, J. A. et al. 2021. Efficient intravenous tumor targeting using the αvβ6 integrin-selective precision virotherapy Ad5NULL-A20. Viruses 13(5), article number: 864. (10.3390/v13050864)
• Detttorre, G. M. et al. 2021. Systemic pro-inflammatory response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection: the OnCovid inflammatory score. Journal for ImmunoTherapy of Cancer 9, article number: e002277. (10.1136/jitc-2020-002277)

2020

• Hulin-Curtis, S. et al. 2020. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Therapy 27, pp. 785-798. (10.1038/s41417-019-0156-0)
• Jones, R. et al. 2020. A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer patients not suitable to receive cisplatin. BJU International 126(2), pp. 292-299. (10.1111/bju.15096)
• Birtle, A. et al. 2020. Adjuvant chemotherapy in upper tract urothelial carcinoma: results of the POUT phase III randomised controlled trial. The Lancet 395(10232), pp. 1268-1277. (10.1016/S0140-6736(20)30415-3)

2018

• Uusi-Kerttula, H. et al. 2018. Ad5NULL-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research 24(17), pp. 4215-4224. (10.1158/1078-0432.CCR-18-1089)
• Hulin-Curtis, S., Davies, J. A., Jones, R., Hudson, E., Hanna, L., Chester, J. D. and Parker, A. L. 2018. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9(41), pp. 26328-26341. (10.18632/oncotarget.25242)
• Collins, J. T. et al. 2018. The value of physical performance measurements alongside assessment of sarcopenia in predicting receipt and completion of planned treatment in non-small cell lung cancer: an observational exploratory study. Supportive Care in Cancer 26, pp. 119-127. (10.1007/s00520-017-3821-6)

2017

• Crabb, S. J. et al. 2017. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. European Journal of Cancer 87, pp. 75-83. (10.1016/j.ejca.2017.09.033)
• Lopes-Bastos, B. et al. 2017. Association of breast carcinoma growth with a non-canonical axis of IFNγ/IDO1/TSP1. Oncotarget (10.18632/oncotarget.18781)
• Dabkowski, A., Paisey, S. J., Spezi, E., Chester, J. and Marshall, C. 2017. Optimization of Zirconium-89 production in IBA cyclone 18/9 cyclotron with COSTIS solid target system. Presented at: WTTC16: Proceedings of the 16th International Workshop on Targetry and Target Chemistry, Santa Fe, NM, USA, 29 August–1 September 2016 Presented at Engle, J. W. et al. eds.AIP Conference Proceedings, Vol. 1845. Melville, NY: AIP pp. 20005., (10.1063/1.4983536)
• Chester, J. D., Bond, J. R. and Batt, E. A. 2017. The Wales Cancer Research Centre: improving cancer care together. ecancermedicalscience 11, article number: ed65. (10.3332/ecancer.2017.ed65)
• Powles, T. et al. 2017. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2–positive metastatic bladder cancer. Journal of Clinical Oncology 35(1), pp. 48-55. (10.1200/JCO.2015.66.3468)

2016

• Hulin-Curtis, S., Uusi-Kerttula, H., Jones, R., Hanna, L., Chester, J. D. and Parker, A. L. 2016. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Therapy 23(7), pp. 229-234. (10.1038/cgt.2016.22)
• Uusi-Kerttula, H., Davies, J., Curtis, S., Chester, J. and Parker, A. 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7(19), pp. 27926-27937. (10.18632/oncotarget.8545)
• Jones, R. J. et al. 2016. TOUCAN: A randomised phase II trial of carboplatin and gemcitabine plus /- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin [Abstract]. American Journal of Clinical Oncology 34(S25), article number: 448.
• Baird, R. et al. 2016. An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. ecancermedicalscience 10, article number: 608. (10.3332/ecancer.2016.608)

2015

• Uusi-Kerttula, H., Davies, J., Coughlan, L., Jones, R., Chester, J. D. and Parker, A. L. 2015. Development of an Ad5 vector pseudotyped with Ad48 knob protein and targeted to αvβ6 integrin efficiently targets tumour cells and evades pre-existing immunity in clinical ascites. Human Gene Therapy 26(9), pp. A33-A33., article number: PO71. (10.1089/hum.2015.29005.abstracts)
• Uusi-Kerttula, H. et al. 2015. Modulation of Ad5 fibre knob as a means of circumventing pre-existing immunity in clinical ovarian ascites. Human Gene Therapy 26(9), pp. A23-A23., article number: PO39. (10.1089/hum.2015.29005.abstracts)
• Hulin-Curtis, S., Uusi-Kerttula, H., Jones, R., Baker, A., Chester, J. D. and Parker, A. L. 2015. Evaluation of CD46 utilising adenoviral vectors for clinical ovarian cancer applications [Abstract]. Human Gene Therapy 26(9), pp. A33-A34., article number: PO72. (10.1089/hum.2015.29005.abstracts)
• Collins, J. et al. 2015. Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol. BMC Cancer 15, pp. 401-413., article number: 544. (10.1186/s12885-015-1565-6)
• Jackson, S. E. and Chester, J. D. 2015. Personalised cancer medicine. International Journal of Cancer 137(2), pp. 262-266. (10.1002/ijc.28940)
• Crusz, S. and Chester, J. D. 2015. Muscle invasive transitional cell carcinoma of the bladder. In: Bhattacharyya, M., Payne, S. and McNeish, I. eds. Challenging Concepts in Oncology. Oxford: Oxford University Press, pp. 133-142.
• Uusi-Kerttula, H. et al. 2015. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fibre knob domain, and their evaluation as targeted cancer therapies. Human Gene Therapy 26(5), pp. 320-329. (10.1089/hum.2015.015)
• Geldart, T. et al. 2015. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology 67(4), pp. 599-602. (10.1016/j.eururo.2014.11.003)
• Sternberg, C. N. et al. 2015. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncology 16(1), pp. 76-86. (10.1016/S1470-2045(14)71160-X)

2014

• Chester, J. D. and Brown, S. R. 2014. Chemo-radio-sensitisation in head and neck cancer. In: Brown, S. R. et al. eds. A Practical Guide to Designing Phase II Trials in Oncology. Statistics in Practice Wiley, pp. 151-159.
• Collins, J., Noble, S. I. R., Chester, J. D., Coles, B. M. and Byrne, A. 2014. The assessment and impact of sarcopenia in lung cancer: a systematic literature review. BMJ Open 4(1), article number: e003697. (10.1136/bmjopen-2013-003697)

2013

• Nicholson, S. et al. 2013. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). British Journal of Cancer 109(10), pp. 2554-2559. (10.1038/bjc.2013.620)
• Jones, R. et al. 2013. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.. Investigational New Drugs 31(4), pp. 1001-1007. (10.1007/s10637-013-9926-y)

2012

• Blick, C. et al. 2012. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.. Cancer 118(16), pp. 3920-3927. (0.1002/cncr.26675)
• Blick, C. et al. 2012. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Cancer 118(16), pp. 3920-3927. (10.1002/cncr.26675)
• Karapanagiotou, E. M. et al. 2012. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clinical Cancer Research 18(7), pp. 2080. (10.1158/1078-0432.CCR-11-2181)
• Conway, C. et al. 2012. Next-generation sequencing for simultaneous determination of human papillomavirus load, subtype, and associated genomic copy number changes in tumors. The Journal of Molecular Diagnostics 14(2), pp. 104-111. (10.1016/j.jmoldx.2011.10.003)
• Karanpanagiotou, E. M. et al. 2012. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.. Clinical Cancer Research 18(7), pp. 2080-2089. (10.1158/1078-0432.CCR-11-2181)

2011

• Harvey, T. J. et al. 2011. Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo. Cancer Gene Therapy 18(11), pp. 773-784. (10.1038/cgt.2011.43)
• Naik, J. D., Twelves, C. J., Selby, P. J., Vile, R. G. and Chester, J. D. 2011. Immune recruitment and therapeutic synergy: Keys to optimizing oncolytic viral therapy?. Clinical Cancer Research 17(13), pp. 4214-4224. (10.1158/1078-0432.CCR-10-2848)
• Kottke, T. et al. 2011. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature Medicine 17(7), pp. 854-859. (10.1038/nm.2390)
• Lamont, F. R., Tomlinson, D. C., Cooper, P. A., Shnyder, S. D., Chester, J. D. and Knowles, M. A. 2011. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. British Journal of Cancer 104(1), pp. 75-82. (10.1038/sj.bjc.6606016)
• Kottke, T. et al. 2011. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors.. Nature Medicine 17(7), pp. 854-859. (10.1038/nm.2390.)
• Kottke, T. et al. 2011. Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.. Molecular Therapy 19(10), pp. 1802-1812. (10.1038/mt.2011.147)
• Rimmer, Y. et al. 2011. Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. British Journal of Cancer 105(6), pp. 766-772. (10.1038/bjc.2011.309)

2010

• Harvey, T. J. et al. 2010. Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. Gene Therapy 17(8), pp. 1000-1010. (10.1038/gt.2010.45)
• Kottke, T. et al. 2010. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. The Journal of Clinical Investigation 120(5), pp. 1551-1560. (10.1172/JCI41431)
• Harrington, K. J., Vile, R. G., Melcher, A., Chester, J. D. and Pandha, H. 2010. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.. Cytokine & Growth Factor Reviews 21(2-3), pp. 91-98.
• Young, A., Madi, A., Treanor, D., Millson, C., Selby, P. and Chester, J. D. 2010. Fulminant hepatic failure in a patient with advanced extragonadal germ cell tumour. BMJ Case Reports 2010 (10.1136/bcr.01.2010.2661)

2009

• Patel, P. et al. 2009. Corrigendum to "A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase With CB1984" (vol 17, pg 1292, 2009) [Corrigendum]. Molecular Therapy 17(7), pp. 1302. (10.1038/mt.2009.110)
• Patel, P. et al. 2009. A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1954. Molecular Therapy 17(7), pp. 1292-1299. (10.1038/mt.2009.80)

2008

• Kottke, T. et al. 2008. Use of biological therapy to enhance both virotherapy and adoptive t-cell therapy for cancer. Molecular Therapy 16(12), pp. 1910-1918. (10.1038/mt.2008.212)
• Karapanagiotou, E. et al. 2008. Phase I Trial of Oncolytic Reovirus (Reolysin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Solid Cancers [Abstract]. Journal of Immunotherapy 31(9), pp. 952. (10.1097/CJI.0b013e31818b1dce)
• Kottke, T. et al. 2008. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Molecular Therapy 16(7), pp. 1217-1226. (10.1038/mt.2008.83)
• Qiao, J. et al. 2008. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Therapy 15(8), pp. 604-616. (10.1038/sj.gt.3303098)
• Seymour, M. T. et al. 2008. A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer. European Journal of Surgical Oncology (EJSO) 34(4), pp. 403-409. (10.1016/j.ejso.2007.05.007)
• Qiao, J. et al. 2008. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nature Medicine 14(1), pp. 37-44. (10.1038/nm1681)

2007

• Theodore, C. et al. 2007. 4502 ORAL Phase 2 study of irinotecan and cisplatin in epidermoid carcinoma of the penis (EORTC 30992) [Abstract]. EJC Supplements 5(4), pp. 299. (10.1016/S1359-6349(07)71133-3)
• Thanarajasingam, U. et al. 2007. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Research 67(1), pp. 300-308. (10.1158/0008-5472.CAN-06-1017)

2006

• Chester, J. D. et al. 2006. Corrigendum: Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells (vol 20, pg 256, 2002) [Corrigendum]. Nature Biotechnology 24(10), pp. 1293. (10.1038/nbt1006-1293b)
• El-Helw, L. M., Naik, J. D., Chester, J. D., Joffe, J. K., Selby, P. J. and Coleman, R. E. 2006. High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours. BJU International 98(3), pp. 519-525. (10.1111/j.1464-410X.2006.06389.x)
• Hall, G. D., Smith, B., Weeks, R. J., Selby, P. J., Southgate, J. and Chester, J. D. 2006. Novel urothelium specific gene expression identified by differential display reverse transcriptase-polymerase chain reaction. The Journal of Urology 175(1), pp. 337-342. (10.1016/S0022-5347(05)00006-6)

2005

• Cole, C. et al. 2005. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nature Medicine 11(10), pp. 1073-1081. (10.1038/nm1297)
• Hall, G. D., Weeks, R. J., Olsburgh, J., Southgate, J., Knowles, M. A., Selby, P. J. and Chester, J. D. 2005. Transcriptional control of the human urothelial-specific gene, uroplakin Ia. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1729(2), pp. 126-134. (10.1016/j.bbaexp.2005.04.004)

2004

• Chester, J. D., Hall, G. D., Forster, M. and Protheroe, A. S. 2004. Systemic chemotherapy for patients with bladder cancer - current controversies and future directions. Cancer Treatment Reviews 30(4), pp. 343-358. (10.1016/j.ctrv.2003.12.005)
• Hennig, I. M., Harvey, T. J., Vile, R. G., Selby, P. S. and Chester, J. D. 2004. Hypoxia-selective expression of systemically-delivered macrophage-based cancer gene therapy vectors for treatment of disseminated malignancy [Abstract]. Annals of Oncology 15(S3), pp. 25.

2003

• Crittenden, M. et al. 2003. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Research 63(12), pp. 3173-3180.
• Hennig, I. et al. 2003. Human endothelial precursor cells as carriers for therapeutic gene delivery to tumors [Abstract]. Molecular Therapy 7(5), pp. S129. (10.1006/mthe.2003.0983)
• Chester, J. D. et al. 2003. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fluorouracil-refractory metastatic colon cancer. Journal of Clinical Oncology 21(6), pp. 1125-1132. (10.1200/JCO.2003.08.049)
• Chester, J. D., Kennedy, W., Hall, G. D., Selby, P. J. and Knowles, M. A. 2003. Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo. Gene Therapy 10(2), pp. 172-179. (10.1038/sj.gt.3301851)

2002

• Cheeseman, S. L., Joel, S. P., Chester, J. D., Wilson, G., Dent, J. T., Richards, F. J. and Seymour, M. T. 2002. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. British Journal of Cancer 87(4), pp. 393-399. (10.1038/sj.bjc.6600467)
• Chester, J. D. et al. 2002. Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nature Biotechnology 20(3), pp. 256-263. (10.1038/nbt0302-256)
• Gough, M. et al. 2002. Using T cells to deliver transgenes to target cells: antigen specific virus production and tissue-specific transgene expression for targeted delivery [Abstract]. FASEB Journal 16(4), pp. A335-A336.

2001

• Emiliusen, L. et al. 2001. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component. Gene Therapy 8(13), pp. 987-998.
• Chester, J. D., Howarth, M., Clark, C. J. P., Goldesbrough, D. R., Bogle, S. E., Bradley, C. J. and Parker, D. 2001. Management of lymphoma patients in a Cancer Unit: An audit of 15 years' experience in a District General Hospital [Abstract]. British Journal of Cancer 85(S1), pp. 72. (10.1054/bjoc.2001.1918)
• Chester, J. D. et al. 2001. Cell-based vector delivery for cancer gene therapy [Abstract]. British Journal of Cancer 85(S1), pp. 24. (10.1054/bjoc.2001.1917)
• Chester, J. D., Clark, C. J. P., Gouldesbrough, D. R., Bogle, S. M., Bradley, C. J. and Parker, D. 2001. Management of lymphoma patients in a cancer unit: An audit of 15 years' experience in a district general hospital. Clinical Oncology 13(4), pp. 243-250. (10.1053/clon.2001.9263)

2000

• Chester, J. D. et al. 2000. A phase I and pharmacokinetic trial of intravenous irinotecan plus oral cyclosporin in 5-FU refractory metastatic colon cancer [Abstract]. Clinical Cancer Research 6(S), pp. 4515.
• Chester, J. D., Dent, J. T., Wilson, G., Ride, E. and Seymour, M. T. 2000. Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Annals of Oncology 11(2), pp. 235-237.

1999

• Chester, J. D., Dent, J. T., Wilson, G., Ride, E. and Seymour, M. T. 1999. Protracted infusional 5FU+mitomycin in 5FU-resistant colorectal cancer [Abstract]. British Journal of Cancer 80(S), pp. 55.

1998

• Wyld, D. K., Chester, J. D. and Perren, T. J. 1998. Endocrine aspects of the clinical management of breast cancer - current issues. Endocrine-Related Cancer 5(2), pp. 97-110. (10.1677/erc.0.0050097)

1991

• Thiele, B. J., Chester, J. D., Oprey, J., Hohne, W. E. and Harrison, P. R. 1991. Structure and regulation of the gene encoding the erythroid-spcecific rabbit 15-lipoxygenase [Abstract]. Biological Chemistry 372(2), pp. 789. (10.1515/bchm3.1991.372.2.785)

1990

• Thiele, B. J. et al. 1990. Structure of the Messenger-RNA and of the gene coding for the Rabbit Erythroid 15-Lipoxygenase. Biomedica Biochimica Acta 49(2-3), pp. S17-S24.
• Harrison, P. R. et al. 1990. Regulation of erythroid-specific gene-expression. Biomedica Biochimica Acta 49(2-3), pp. S5-S10.

1989

• Oprey, J., Chester, J. D., Thiele, B. J., Janetzki, S., Prehn, S., Fleming, J. and Harrison, P. R. 1989. The promoter structure and complete sequence of the gene encoding the rabbit erythroid cell-specific 15-lipoxygenase. Gene 84(2), pp. 493-499. (10.1016/0378-1119(89)90526-X)
• Fleming, J. et al. 1989. The complete sequence of the rabbit erythroid cell-specific 15-lipoxygenase mRNA: comparison of the predicted amino acid sequence of the erythrocyte lipoxygenase with other lipoxygenases. Gene 79(1), pp. 181-188. (10.1016/0378-1119(89)90103-0)

1988

• Harrison, P. R. et al. 1988. Regulation of erythroid cell-specific gene expression during erythropoiesis. British Journal of Cancer Supplement 58(S), pp. 46-51.
• Harrison, P. R. et al. 1988. cis and trans control of erythroid cell-specific gene expression during erythropoiesis. Journal of Cell Science(S10), pp. 145-155.

1987

• Thiele, B. J. et al. 1987. Cloning of a rabbit erythroid-cell-specific lipoxygenase mRNA. Gene 57(1), pp. 111-119. (10.1016/0378-1119(87)90182-X)

1985

• Fulton, A. M. et al. 1985. Variants within the yeast Ty sequence family encode a class of structurally conserved proteins. Nucleic Acids Research 13(11), pp. 4097-4112. (10.1093/nar/13.11.4097)